First-in-class checkpoint inhibitor BI 765063 licensed to and being developed under a collaboration agreement between Boehringer Ingelheim and OSE Immunotherapeutics
Clinical Trial Authorization and dosing of the first patient triggers a total of €15 million milestone payments from Boehringer Ingelheim to OSE Immunotherapeutics
INGELHEIM, Germany & NANTES, France -- (BUSINESS WIRE) --
Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumors. The Phase 1 study is a dose finding study of BI 765063, a myeloid checkpoint inhibitor, administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a T-lymphocyte checkpoint inhibitor.
“We are very pleased with the progress achieved on BI 765063’s program and having the first patient dosed marks a significant milestone in the product’s development. The advancement of a myeloid cell checkpoint blocking monoclonal antibody into the clinic exemplifies Boehringer Ingelheim’s commitment to the next wave of innovation in cancer immunology therapies, with the goal of meaningfully improving outcomes for patients with difficult-to-treat cancers” said Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head, Cancer Immunology & Immune Modulation Research at Boehringer Ingelheim.
“We are excited to begin first-in-human testing with this novel SIRPα-targeting compound, which we believe has first-in-class potential in the treatment of solid tumors,” said Alexis Peyroles, chief executive officer of OSE Immunotherapeutics. “This marks one of many anticipated milestones in the collaboration agreement with our partner Boehringer Ingelheim, and we look forward to advancing rapidly this potentially transformative treatment through the clinic. Milestones such as this one for the novel compounds our R&D teams develop have provided OSE with a stable financial base to grow steadily our first-in-class immuno-oncology pipeline.”
The study is conducted by OSE Immunotherapeutics as part of a collaboration and license agreement under which Boehringer Ingelheim obtained exclusive rights to BI 765063. Under the terms of the collaboration and license agreement, the clinical trial authorization obtained in March 2019 and dosing of the first patient in this Phase 1 trial triggers milestone payments of a total of €15 million to OSE Immunotherapeutics from Boehringer Ingelheim. This trial aims to characterize safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the immunotherapy in patients with advanced solid tumours.
Please click on the link for “Notes to the Editors” and “References”
沙特发展基金为塔吉克斯坦新公立学校举行落成
走进中国工笔画名家杨明玉的艺术魅力
KPMG and Microsoft Enter
雷蛇公布2019年全年业绩
芯和半导体在DesignCon2023大会上发布新品
欧洲量子物理和人工智能领导者泰雷兹宣布20
上饶信州中专开展春季校园食堂安全隐患自查
BODY JAZZ入驻SKP, 感恩一路有你
河南中牟县数十万多件农耕老物件寻找有缘人
Energy Vault和DG Fuels将初始储能
“全球印度人”继续在国际商业中扮演重要角色
滨城区学院附小2014级六(2)中队世界读书日活
9/11 Day与Epik合作推出全球首个NFT
企业品牌营销找中秘传媒 新闻宣传推广效果好
NetWitness推出12.3版更新,可为整个企业
技嘉科技(GIGABYTE)的人工智能实力在
Celgene Submits Application
淮安市少儿图书馆“结对子•种文化”活动走进
索尔思光电在OFC 2019展示最新400G
国际化高端人才培养工程在京启动
位于阿布扎比的技术创新研究所安全系
松下与Institute of Microchemical
2020新品巡展于青岛利群金鼎广场 盛大开启
Optomec公布数字化制造愿景,助力客户迈向未来